JPS58193689A - テストステロン−５α−レダクタ−ゼ阻害剤 - Google Patents
テストステロン−５α−レダクタ−ゼ阻害剤Info
- Publication number
- JPS58193689A JPS58193689A JP7772582A JP7772582A JPS58193689A JP S58193689 A JPS58193689 A JP S58193689A JP 7772582 A JP7772582 A JP 7772582A JP 7772582 A JP7772582 A JP 7772582A JP S58193689 A JPS58193689 A JP S58193689A
- Authority
- JP
- Japan
- Prior art keywords
- testosterone
- 5alpha
- tocopherylquinone
- reductase
- reductase inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010029908 3-oxo-5-alpha-steroid 4-dehydrogenase Proteins 0.000 title claims abstract description 16
- 102000001779 3-oxo-5-alpha-steroid 4-dehydrogenase Human genes 0.000 title claims abstract description 16
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 title claims abstract description 8
- 239000002677 5-alpha reductase inhibitor Substances 0.000 title claims abstract description 8
- LTVDFSLWFKLJDQ-IEOSBIPESA-N 2-[(3r,7r,11r)-3-hydroxy-3,7,11,15-tetramethylhexadecyl]-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O LTVDFSLWFKLJDQ-IEOSBIPESA-N 0.000 claims abstract description 13
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract description 6
- 230000003054 hormonal effect Effects 0.000 abstract description 6
- 239000003112 inhibitor Substances 0.000 abstract description 6
- 201000004384 Alopecia Diseases 0.000 abstract description 5
- 239000003098 androgen Substances 0.000 abstract description 4
- 206010068168 androgenetic alopecia Diseases 0.000 abstract description 4
- 229960003604 testosterone Drugs 0.000 abstract description 4
- 206010039792 Seborrhoea Diseases 0.000 abstract description 3
- 208000008742 seborrheic dermatitis Diseases 0.000 abstract description 3
- 231100000957 no side effect Toxicity 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- YSJVXRLCNZMPFO-VHFRWLAGSA-N 2-[(3r,7r,11r)-3-hydroxy-3,7,11,15-tetramethylhexadecyl]-6-methylcyclohexa-2,5-diene-1,4-dione Chemical class CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@](C)(O)CCC1=CC(=O)C=C(C)C1=O YSJVXRLCNZMPFO-VHFRWLAGSA-N 0.000 abstract 1
- XEXGHDCZBILZDD-DQCZWYHMSA-N 5-[(3r,7r,11r)-3-hydroxy-3,7,11,15-tetramethylhexadecyl]-2,3-dimethylcyclohexa-2,5-diene-1,4-dione Chemical class CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@](C)(O)CCC1=CC(=O)C(C)=C(C)C1=O XEXGHDCZBILZDD-DQCZWYHMSA-N 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000030961 allergic reaction Diseases 0.000 abstract 1
- ITLZIXCIULJMPV-UHFFFAOYSA-N beta-Tocopheryl quinone Chemical class CC(C)CCCC(C)CCCC(C)CCCC(C)(O)CCC1=C(C)C(=O)C=C(C)C1=O ITLZIXCIULJMPV-UHFFFAOYSA-N 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000007794 irritation Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 description 7
- 210000001732 sebaceous gland Anatomy 0.000 description 5
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 229940030486 androgens Drugs 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical group 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 150000003611 tocopherol derivatives Chemical class 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Landscapes
- Enzymes And Modification Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7772582A JPS58193689A (ja) | 1982-05-10 | 1982-05-10 | テストステロン−５α−レダクタ−ゼ阻害剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7772582A JPS58193689A (ja) | 1982-05-10 | 1982-05-10 | テストステロン−５α−レダクタ−ゼ阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58193689A true JPS58193689A (ja) | 1983-11-11 |
| JPS644758B2 JPS644758B2 (enrdf_load_stackoverflow) | 1989-01-26 |
Family
ID=13641869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP7772582A Granted JPS58193689A (ja) | 1982-05-10 | 1982-05-10 | テストステロン−５α−レダクタ−ゼ阻害剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS58193689A (enrdf_load_stackoverflow) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7432305B2 (en) | 2005-09-15 | 2008-10-07 | Edison Pharmaceuticals, Inc. | Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| EP2471530A1 (en) | 2005-06-01 | 2012-07-04 | Edison Pharmaceuticals, Inc. | Redox-active Therapeutics For Treatment Of Mitochondrial Diseases And Other Conditions And Modulation Of Energy Biomarkers |
| US9278085B2 (en) | 2006-02-22 | 2016-03-08 | Edison Pharmaceuticals, Inc. | Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| US10105325B2 (en) | 2008-09-10 | 2018-10-23 | Bioelectron Technology Corporation | Treatment of pervasive developmental disorders with redox-active therapeutics |
| US10703701B2 (en) | 2015-12-17 | 2020-07-07 | Ptc Therapeutics, Inc. | Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0444572A (ja) * | 1990-06-11 | 1992-02-14 | Toto Ltd | 太陽灯付ユニットバスルーム |
-
1982
- 1982-05-10 JP JP7772582A patent/JPS58193689A/ja active Granted
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2471530A1 (en) | 2005-06-01 | 2012-07-04 | Edison Pharmaceuticals, Inc. | Redox-active Therapeutics For Treatment Of Mitochondrial Diseases And Other Conditions And Modulation Of Energy Biomarkers |
| EP2564843A1 (en) | 2005-06-01 | 2013-03-06 | Edison Pharmaceuticals, Inc. | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| EP2564842A1 (en) | 2005-06-01 | 2013-03-06 | Edison Pharmaceuticals, Inc. | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| US11021424B2 (en) | 2005-06-01 | 2021-06-01 | Ptc Therapeutics, Inc. | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| US9447006B2 (en) | 2005-06-01 | 2016-09-20 | Edison Pharmaceuticals, Inc. | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| US7432305B2 (en) | 2005-09-15 | 2008-10-07 | Edison Pharmaceuticals, Inc. | Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| US9932286B2 (en) | 2006-02-22 | 2018-04-03 | Bioelectron Technology Corporation | Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| US9278085B2 (en) | 2006-02-22 | 2016-03-08 | Edison Pharmaceuticals, Inc. | Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| US10105325B2 (en) | 2008-09-10 | 2018-10-23 | Bioelectron Technology Corporation | Treatment of pervasive developmental disorders with redox-active therapeutics |
| US10736857B2 (en) | 2008-09-10 | 2020-08-11 | Ptc Therapeutics, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
| US10703701B2 (en) | 2015-12-17 | 2020-07-07 | Ptc Therapeutics, Inc. | Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| US10981855B2 (en) | 2015-12-17 | 2021-04-20 | Ptc Therapeutics, Inc. | Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| US11680034B2 (en) | 2015-12-17 | 2023-06-20 | Ptc Therapeutics, Inc. | Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS644758B2 (enrdf_load_stackoverflow) | 1989-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0412756A (pt) | composições para tratamento de pele | |
| US12357558B2 (en) | Topical skincare compositions comprising Centella asiatica | |
| Brandner et al. | Caffeine improves barrier function in male skin | |
| JPS58193689A (ja) | テストステロン−５α−レダクタ−ゼ阻害剤 | |
| JPS6284021A (ja) | テストステロン−５α−レダクタ−ゼ阻害剤 | |
| JP2015501803A (ja) | 二酸化塩素含有育毛溶液及びその調製並びに使用方法 | |
| EP1253966B1 (de) | Substanzen und mittel zur positiven beeinflussung von kollagen | |
| JPS63203625A (ja) | ５α−リダクタ−ゼ阻害剤 | |
| CN104287982B (zh) | 一种调节头皮油脂平衡的去屑组合物 | |
| US5609858A (en) | Method for treatment of androgenic alopecia | |
| RU2004119850A (ru) | Композиция на основе сложного диосгенина для топического нанесения | |
| Marks et al. | Glucocorticoid-induced vasoconstriction in human skin: an inhibitory role on phospholipase A2 activity | |
| EP4373496A1 (en) | Composition or formulation comprising one or more 5-alpha-reductase inhibitors and one or more bile acids | |
| JPH02193920A (ja) | ５α―リダクターゼ阻害剤 | |
| JPH0420892B2 (enrdf_load_stackoverflow) | ||
| JPH0380769B2 (enrdf_load_stackoverflow) | ||
| JPS5953418A (ja) | 皮膚外用剤 | |
| JPH0112725B2 (enrdf_load_stackoverflow) | ||
| US6399085B1 (en) | Method of moisturizing the skin by the topical application of Δ5-androstene-3β-ol-7,17 dione and metabolizable precursors thereof | |
| Behrman | Diagnosis and management of hirsutism | |
| US8530435B2 (en) | Brassinosteroids in treating prostatic hyperplasia and androgenic alopecia | |
| EP2101798A2 (en) | Topical treatment of acne with extracts of glycyrrhiza, foeniculum and atriplex, combined with minerals | |
| RU2683770C1 (ru) | Способ получения липосомальной формы соли 2-этил-6-метил-3-гидроксипиридина с никотиновой кислотой, ее применение для улучшения микроциркуляции в коже | |
| JPH0196125A (ja) | ５α‐リダクターゼ阻害剤 | |
| JP2000103765A (ja) | 新規なトリテルペン類およびこれを含有する組成物 |